Recent Updates
Recently added Catalysts
NTRB Positive Sentiment

Nutriband CEO, Gareth Sheridan to Attend the Nasdaq Life Sciences Advisory Board (LaB) Biotech Summit

Key Takeaway: Nutriband Inc. announced that CEO Gareth Sheridan will attend the inaugural Nasdaq LaB Biotech Summit on September 16th. The event will facilitate networking among biotechnology executives and investors. The company is focused on developing its AVERSA™ abuse-deterrent transdermal technology, which aims to enhance the safety of drugs like fentanyl.
Price reaction · baseline $6.1 (2026-09-08 close) · hit pre-market · clean, no other NTRB news in the window
day 0 close · peak
-4.9%

Market Sentiment Analysis

POSITIVE FACTORS

  • CEO Gareth Sheridan will attend a prominent biotech summit.
  • The AVERSA™ technology aims to improve drug safety.
  • Nutriband has a broad intellectual property portfolio.

Full Press Release Details

ORLANDO, Fla., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB)(NASDAQ:NTRBW), today announced that its CEO, Gareth Sheridan will attend the inaugural Nasdaq LaB Biotech Summit on September 16th. The Summit brings together biotechnology executives, investors, and industry leaders for an evening of thought leadership and networking at Nasdaq MarketSite in New York.

About AVERSA™ Abuse-Deterrent Transdermal Technology

Nutriband's AVERSA™ abuse-deterrent transdermal technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The AVERSA™ abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible to those patients who really need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.

About Nutriband Inc.

We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
The Company's website is www.nutriband.com. Any material contained in or derived from the Company's websites or any other website is not part of this press release.

Forward-Looking Statements

Certain statements contained in this press release, including, without limitation, statements containing the words ‘'believes," "anticipates," "expects" and words of similar import, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company's actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company's ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company's business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Form S-1, Forms 10-K’s and Forms 10-Q’s, and the Company's other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.
Contact Information:
Nutriband Inc. Phone: 407-377-6695 Email: info@nutriband.com
SOURCE: Nutriband Inc.

Frequently Asked Questions

What is the Nasdaq LaB Biotech Summit?

The Nasdaq LaB Biotech Summit is an event for biotech executives and investors.

What technology does Nutriband's AVERSA™ use?

AVERSA™ incorporates aversive agents into transdermal patches to prevent drug abuse.

When will the Nasdaq Biotech Summit take place?

The summit is scheduled for September 16th.

What is Nutriband's lead product?

Nutriband's lead product is an abuse-deterrent fentanyl patch.

Last updated: Sep 9, 2026